Cancer Biomarker Testing Market: By Type Of Cancer (Cervical cancer, Lung Cancer, Collateral Cancer, Liver Cancer, Prostate Cancer, Breast Cancer, Others), By Application (Drug Discovery and Development, Personalised Medicine, Diagnosis, Others), By End-User (Hospitals, Cancer diagnostic Centres, Research Institutes, Others) and Geography  

Purchase Option

$ 4400
$ 6600
$ 8900

Cancer Biomarker Testing Market Size was valued at USD 10.42 billion in 2022 and is poised to grow at a significant CAGR of 15.4% from 2024-2030. The cancer biomarker test market is driven by The increasing use of cancer biomarkers in drug discovery and development, along with growing research in this area, technological advancements, and the rising global incidence of cancer, are all contributing to significant advancements in cancer diagnosis, treatment, and patient care. World Health Organization (WHO) stated that cancer is one of the leading causes of mortality and morbidity worldwide, with approximately 14 Mn new cases in 2012. The number of new cases is expected to rise about 70% over the coming 2 decades.

In addition, increase in awareness in public and healthcare professionals regarding early diagnostic procedures, rise in government and NGO's funding for oncology are expected to bolster the cancer biomarker testing market. Furthermore, the development of companion diagnostics and recent breakthrough in detection techniques such as proteomics, metabolomics, genomics and transcriptomics are further expected to boost the cancer biomarker test market. However, high cost for biomarker tests, low detection rates and regulatory policies are expected to hamper the cancer biomarker test market. and Regulatory agencies like the U.S. Food and Drug Administration (FDA) were providing guidance on the development and validation of biomarkers for clinical use. Streamlining regulatory pathways for biomarker-based tests was important for their clinical adoption. The global market is expected to grow with significant CAGR during forecast period. Market players are carrying out collaborations, partnerships, and acquisitions as key development strategies to enhance the market share.

The Cancer Biomarker Testing Market Key Developments :
  • In April 2021, F. Hoffmann-La Roche Ltd. indeed launched the Elecsys Anti-p53 immunoassay, which is designed to aid in the diagnosis of various cancer types.
  • In March 2017, Foundation Medicine and Bristol-Myers Squibb entered collaboration to understand tumour profile and its microenvironment to predict patient's response to cancer immunotherapy. Using Foundation Medicine's foundation genomic profiling assay, the firm will look at tumour mutational burden and microsatellite instability in patients enrolled in clinical trials for Bristol-Myers Squibb (BMS) cancer drugs.
  • In October 2016, Arquer Diagnostics Ltd. (Arquer), and University of Sunderland are collaborated to investigate noninvasive specimen preparation techniques that will facilitate the use of Arquer's MCM5-ELISA test in a wide range of cancers.
  • In April 2016, Stemcentrix acquired by AbbiVe along with its lead late stage biomarker rovalpituzumab tesirine (Rova-T), that helps to identify tumour cells.
  • In 2015, Abbot Laboratories acquired exclusive rights for FGFR3 gene mutations to detect bladder cancer. FGFR3 developed at Institute Curie, it is a gene mutation and useful for early detection, disease monitoring, and prognosis of bladder cancer through tissue and urine-based testing.  

Global Cancer Biomarker Testing Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

15.4%

Largest Market

North America

Fastest Growing Market

North-America
Cancer Biomarker Testing Market Dynamics

Companion diagnostics, tailored medications, and other disease diagnostics, such as disease risk assessment and drug research and development, all rely heavily on cancer biomarkers. One of the primary reasons likely to boost cancer biomarkers market growth during the projected period of 2023-2029 is the increased utilisation of biomarkers in disease diagnosis. The rising global prevalence of cancer is driving the need for early disease detection, which is propelling the market forward. According to the National Cancer Institute, 1,735,350 new cancer cases were reported in the United States in 2018. In addition, the World Cancer Research Fund International estimates that 18.0 million individuals worldwide were affected by cancer in 2018. Lung and breast cancers were the most prevalent cancers reported globally in 2018, accounting for 12.3 percent of all cases diagnosed. The increased incidence of cancer biomarkers in both developing and developed countries is expected to boost demand for cancer diagnostics and therapy. During the projection period. these factors are expected to boost demand for these biomarkers. Despite the rising global incidence of cancer and the increasing number of patients requiring diagnostic tests, the lack of reimbursement regulations for biomarker tests in emerging and industrialised nations is one issue restricting global demand for these biomarkers. Another key stumbling block to the market's expansion is the high cost of cancer diagnosis and treatment in developing countries. This is reducing the number of patients who are tested for biomarkers, and patients are increasingly preferring other low-cost detection tests. As immunotherapy gained prominence as a cancer treatment approach, identifying biomarkers that could predict patient responses to immunotherapies (such as PD-L1 expression) became crucial for optimizing treatment strategies.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

Global Cancer Biomarker Testing Market Segmentation

By Type of Cancer
  • Cervical cancer
  • Lung Cancer
  • Collateral Cancer
  • Liver Cancer
  • Prostate Cancer
  • Breast Cancer
  • Others
By Application
  • Drug Discovery and Development
  • Personalised Medicine
  • Diagnosis
  • Others
By End User
  • Hospitals
  • Cancer diagnostic Centres
  • Research Institutes
  • Others

Frequently Asked Questions

The Cancer Biomarker Testing Market was expected to grow at a significant compound annual growth rate (CAGR) of 15.4% from 2023 to 2029. Additionally, it mentions that the market value was USD 10.42 billion in 2022.

Thermo Fisher Scientific  (Affymetrix Inc.), Abbott Laboratories, F. Hoffmann-La Roche Ltd., AbbVie Inc.Arquer Diagnostics Ltd., Illumina, Inc.

Asia-Pacific is the fastest-growing region for cancer biomarker testing market

1.Executive Summary
2.Global Cancer Biomarker Testing Market Introduction 
2.1.Global Cancer Biomarker Testing Market  - Taxonomy
2.2.Global Cancer Biomarker Testing Market  - Definitions
2.2.1.Type of Cancer
2.2.2. Application
2.2.3. End User 
2.2.4.Region
3.Global Cancer Biomarker Testing Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Cancer Biomarker Testing Market Analysis, 2019 - 2023 and Forecast 2024 - 2030
4.1.  Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Cancer Biomarker Testing Market  By Type of Cancer, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
5.1. Cervical cancer
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Lung Cancer
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Collateral Cancer
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
5.4. Liver Cancer
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.4.3. Market Opportunity Analysis 
5.5. Prostate Cancer
5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.5.3. Market Opportunity Analysis 
5.6. Breast Cancer
5.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.6.3. Market Opportunity Analysis 
5.7. Others
5.7.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.7.3. Market Opportunity Analysis 
6.Global Cancer Biomarker Testing Market  By  Application, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
6.1. Drug Discovery and Development
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Personalised Medicine
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Diagnosis
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
6.4. Others
6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.4.3. Market Opportunity Analysis 
7.Global Cancer Biomarker Testing Market  By  End User , 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
7.1. Hospitals
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Cancer diagnostic Centres
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Research Institutes
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
7.4. Others
7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.4.3. Market Opportunity Analysis 
8.Global Cancer Biomarker Testing Market  By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Europe
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Asia Pacific (APAC)
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Middle East and Africa (MEA)
8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
8.5. Latin America
8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.5.3. Market Opportunity Analysis 
9.North America Cancer Biomarker Testing Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
9.1. Type of Cancer Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.Cervical cancer
9.1.2.Lung Cancer
9.1.3.Collateral Cancer
9.1.4.Liver Cancer
9.1.5.Prostate Cancer
9.1.6.Breast Cancer
9.1.7.Others
9.2.   Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.Drug Discovery and Development
9.2.2.Personalised Medicine
9.2.3.Diagnosis
9.2.4.Others
9.3.   End User  Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Hospitals
9.3.2.Cancer diagnostic Centres
9.3.3.Research Institutes
9.3.4.Others
9.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.4.1.United States of America (USA)
9.4.2.Canada
10.Europe Cancer Biomarker Testing Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
10.1. Type of Cancer Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Cervical cancer
10.1.2.Lung Cancer
10.1.3.Collateral Cancer
10.1.4.Liver Cancer
10.1.5.Prostate Cancer
10.1.6.Breast Cancer
10.1.7.Others
10.2.   Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Drug Discovery and Development
10.2.2.Personalised Medicine
10.2.3.Diagnosis
10.2.4.Others
10.3.   End User  Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Hospitals
10.3.2.Cancer diagnostic Centres
10.3.3.Research Institutes
10.3.4.Others
10.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Germany
10.4.2.France
10.4.3.Italy
10.4.4.United Kingdom (UK)
10.4.5.Spain
11.Asia Pacific (APAC) Cancer Biomarker Testing Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
11.1. Type of Cancer Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Cervical cancer
11.1.2.Lung Cancer
11.1.3.Collateral Cancer
11.1.4.Liver Cancer
11.1.5.Prostate Cancer
11.1.6.Breast Cancer
11.1.7.Others
11.2.   Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Drug Discovery and Development
11.2.2.Personalised Medicine
11.2.3.Diagnosis
11.2.4.Others
11.3.   End User  Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Hospitals
11.3.2.Cancer diagnostic Centres
11.3.3.Research Institutes
11.3.4.Others
11.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.China
11.4.2.India
11.4.3.Australia and New Zealand (ANZ)
11.4.4.Japan
11.4.5.Rest of APAC
12.Middle East and Africa (MEA) Cancer Biomarker Testing Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
12.1. Type of Cancer Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Cervical cancer
12.1.2.Lung Cancer
12.1.3.Collateral Cancer
12.1.4.Liver Cancer
12.1.5.Prostate Cancer
12.1.6.Breast Cancer
12.1.7.Others
12.2.   Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Drug Discovery and Development
12.2.2.Personalised Medicine
12.2.3.Diagnosis
12.2.4.Others
12.3.   End User  Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Hospitals
12.3.2.Cancer diagnostic Centres
12.3.3.Research Institutes
12.3.4.Others
12.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.GCC Countries
12.4.2.South Africa
12.4.3.Rest of MEA
13.Latin America Cancer Biomarker Testing Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
13.1. Type of Cancer Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Cervical cancer
13.1.2.Lung Cancer
13.1.3.Collateral Cancer
13.1.4.Liver Cancer
13.1.5.Prostate Cancer
13.1.6.Breast Cancer
13.1.7.Others
13.2.   Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Drug Discovery and Development
13.2.2.Personalised Medicine
13.2.3.Diagnosis
13.2.4.Others
13.3.   End User  Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Hospitals
13.3.2.Cancer diagnostic Centres
13.3.3.Research Institutes
13.3.4.Others
13.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Brazil
13.4.2.Mexico
13.4.3.Rest of LA
14. Competition Landscape
14.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
14.2.1.Thermo Fisher Scientific  (Affymetrix Inc.) (U.S.)
14.2.2.Abbott Laboratories (U.S.)
14.2.3.F. Hoffmann-La Roche Ltd. (Switzerland)
14.2.4.AbbVie Inc. (U.S.)
14.2.5.Arquer Diagnostics Ltd. (U.K.)
14.2.6.Illumina, Inc. (U.S.)
14.2.7.Qiagen (Germany)
14.2.8.Agilent Technologies (U.S.)
14.2.9.Merck & Co. Inc. (U.S.)
14.2.10.Becton Dickinson and Company (U.S.)
14.2.11.Hologic Inc. (U.S.)
15. Research Methodology 
16. Appendix and Abbreviations 
  • Thermo Fisher Scientific  (Affymetrix Inc.) (U.S.)
  • Abbott Laboratories (U.S.)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • AbbVie Inc. (U.S.)
  • Arquer Diagnostics Ltd. (U.K.)
  • Illumina, Inc. (U.S.)
  • Qiagen (Germany)
  • Agilent Technologies (U.S.)
  • Merck & Co. Inc. (U.S.)
  • Becton Dickinson and Company (U.S.)
  • Hologic Inc. (U.S.)

Adjacent Markets